The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.
Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback